Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network

Affiliations

¹ Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Jaeb Center for Health Research, Tampa, Florida.
³ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland4Editor in Chief, JAMA Ophthalmology.

Comparative Study

Lee M Jampol et al. JAMA Ophthalmol. 2015 Sep.

. 2015 Sep;133(9):983-4.

doi: 10.1001/jamaophthalmol.2015.1880.

¹ Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Jaeb Center for Health Research, Tampa, Florida.
³ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland4Editor in Chief, JAMA Ophthalmology.

No abstract available

References

1. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40. - PMC - PubMed
1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7. - PubMed
1. Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA. 2014;311(22):2269–70. - PMC - PubMed
1. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology. 2015;122(2):375–81. - PMC - PubMed
1. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77. e35. - PMC - PubMed